62 related articles for article (PubMed ID: 1624733)
1. [Renal toxicity of intraperitoneal cisplatin: a case report].
Thomas C; Quinio P
J Gynecol Obstet Biol Reprod (Paris); 1992; 21(4):445-6. PubMed ID: 1624733
[TBL] [Abstract][Full Text] [Related]
2. Irreversible renal failure after intraperitoneal cisplatin administration. A case report.
Gouge SF; Tietjen DP; Moore J
J Reprod Med; 1989 Nov; 34(11):931-3. PubMed ID: 2585396
[TBL] [Abstract][Full Text] [Related]
3. Contrast media induced irreversible acute renal failure in a patient treated with intraperitoneal cisplatin.
Oymak O
Clin Nephrol; 1995 Aug; 44(2):135-6. PubMed ID: 8529307
[No Abstract] [Full Text] [Related]
4. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature.
McDonald BR; Kirmani S; Vasquez M; Mehta RL
Am J Med; 1991 Mar; 90(3):386-91. PubMed ID: 2003521
[TBL] [Abstract][Full Text] [Related]
5. [Renal toxicity by intraperitoneal administration of CDDP].
Chen JT; Yamashiro T; Shimizu Y; Kuo TC; Nakayama K; Teshima H; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):534-40. PubMed ID: 3385274
[TBL] [Abstract][Full Text] [Related]
6. [A case report of acute renal failure induced by melphalan in a patient with ovarian cancer].
Kashimura M; Kondo M; Abe T; Shinohara M; Baba S
Gan No Rinsho; 1988 Nov; 34(14):2015-8. PubMed ID: 2849690
[TBL] [Abstract][Full Text] [Related]
7. Acute renal failure due to cisplatin.
De Santo NG; Capasso G; Capodicasa G; Tancredi F; Nuzzi F; Giordano C
Int J Pediatr Nephrol; 1986; 7(3):145-50. PubMed ID: 3804579
[TBL] [Abstract][Full Text] [Related]
8. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
van der Vange N; van Goethem AR; Zoetmulder FA; Kaag MM; van de Vaart PJ; ten Bokkel Huinink WW; Beijnen JH
Eur J Surg Oncol; 2000 Nov; 26(7):663-8. PubMed ID: 11078613
[TBL] [Abstract][Full Text] [Related]
9. [A case report of advanced ovarian cancer with chronic renal dysfunction treated by CDDP i.p].
Maruyama M; Noda T; Kiyozuka Y; Oku M; Ninomiya Y; Ibaraki T; Katoh Y; Itani Y; Okamura Y; Beppu K
Gan No Rinsho; 1988 May; 34(6):815-9. PubMed ID: 3379761
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
11. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure.
Bennett WM; Pastore L; Houghton DC
Cancer Treat Rep; 1980; 64(8-9):921-4. PubMed ID: 6160913
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure.
Gomez Campdera FJ; Gonzalez P; Carrillo A; Estelles MC; Rengel M
Int J Pediatr Nephrol; 1986; 7(3):151-2. PubMed ID: 3804580
[TBL] [Abstract][Full Text] [Related]
14. [Life threatening anaphylaxis after repeated cisplatin administration: case report and neu therapy concepts].
Berg K; Grundmann U; Villena-Heinsen C; Wilhelm W; Mertzlufft F
Zentralbl Gynakol; 1996; 118(12):684-8. PubMed ID: 9082708
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
16. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
Serkies K; Jassem J
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
[TBL] [Abstract][Full Text] [Related]
17. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
18. Limits to the "benefits" from our oncologic interventions: a case report.
Markman M
Gynecol Oncol; 2000 Aug; 78(2):261-2. PubMed ID: 10926815
[TBL] [Abstract][Full Text] [Related]
19. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
[TBL] [Abstract][Full Text] [Related]
20. High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results.
Bruzzone M; Conte PF; Chiara S; Carnino F; Giaccone G; Conio A; Bentivoglio G; Pescetto G; Rosso R
Chemioterapia; 1985 Apr; 4(2):139-42. PubMed ID: 3891114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
